Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 20, 2015 - Issue 4
Submit an article Journal homepage
615
Views
26
CrossRef citations to date
0
Altmetric
Reviews

Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS)

Teruyuki OgawaDepartment of Urology, University of Pittsburgh, School of Medicine, Suite 700 Kaufmann Medical Building, 3471 Fifth Ave., Pittsburgh, PA 15213, USA;Department of Urology, School of Medicine, Shinshu University, Matsumoto, Japan
,
Osamu IshizukaDepartment of Urology, School of Medicine, Shinshu University, Matsumoto, Japan
,
Tomohiro UedaDepartment of Urology, Ueda Clinic, Kyoto, Japan
,
Pradeep TyagiDepartment of Urology, University of Pittsburgh, School of Medicine, Suite 700 Kaufmann Medical Building, 3471 Fifth Ave., Pittsburgh, PA 15213, USA
,
Michael B ChancellorDepartment of Urology, Oakland University, William Beaumont School of Medicine, Royal Oak, MI, USA
&
Naoki YoshimuraDepartment of Urology, University of Pittsburgh, School of Medicine, Suite 700 Kaufmann Medical Building, 3471 Fifth Ave., Pittsburgh, PA 15213, USA;Department of Urology, Ueda Clinic, Kyoto, JapanCorrespondence[email protected]
Pages 555-570 | Published online: 04 Nov 2015

Bibliography

  • Hunner G. A rare type of bladder ulcer in women; report of cases. Boston Med Surg J. 1915;172:660–664.
  • Fall M, Logadottir Y, Peeker R. Interstitial cystitis is bladder pain syndrome with Hunner’s lesion. Int J Urol. 2014;21(Suppl 1):79–82.

* The characteristics and current status of Hunner’s lesion in IC/BPS are well summarized.

  • Yoshimura N, Seki S, Chancellor MB, et al. Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. Urology. 2002;59(5 Suppl 1):61–67.
  • Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162–2170.

** This AUA guideline describes the definition of IC/BPS and current clinical treatment option, which would be useful for designing the future clinical investigations of IC/BPS.

* The standardized methods for the diagnosis of IC/BPS including cystoscopic evaluation are well described.

  • Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J Urol. 1988;140(1):203–206.
  • Ibrahim IA, Diokno AC, Killinger KA, et al. Prevalence of self-reported interstitial cystitis (IC) and interstitial-cystitis-like symptoms among adult women in the community. Int Urol Nephrol. 2007;39(2):489–495.
  • Bosch PC, Bosch DC. Treating interstitial cystitis/bladder pain syndrome as a chronic disease. Rev Urol. 2014;16(2):83–87.
  • Fall M, Baranowski AP, Elneil S, et al. EAU guidelines on chronic pelvic pain. Eur Urol. 2010;57(1):35–48.

** This EAU guideline is useful for defining the treatment strategies for not only IC/BPS, but also CPPS

  • Logadottir Y, Fall M, Kabjorn-Gustafsson C, et al. Clinical characteristics differ considerably between phenotypes of bladder pain syndrome/interstitial cystitis. Scand J Urol Nephrol. 2012;46(5):365–370.
  • Waxman JA, Sulak PJ, Kuehl TJ. Cystoscopic findings consistent with interstitial cystitis in normal women undergoing tubal ligation. J Urol. 1998;160(5):1663–1667.
  • Peeker R, Fall M. Treatment guidelines for classic and non-ulcer interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(1):23–32.
  • Furuya R, Masumori N, Furuya S, et al. Glomerulation observed during transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is a common finding but no predictor of clinical outcome. Urology. 2007;70(5):922–926.
  • Simon LJ, Landis JR, Erickson DR, et al. The Interstitial Cystitis Data Base Study: concepts and preliminary baseline descriptive statistics. Urology. 1997;49(5A Suppl):64–75.
  • Chancellor MB, Yoshimura N. Treatment of interstitial cystitis. Urology. 2004;63(3 Suppl 1):85–92.
  • Lilly JD, Parsons CL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet. 1990;171(6):493–496.
  • Buffington CA, Woodworth BE. Excretion of fluorescein in the urine of women with interstitial cystitis. J Urol. 1997;158(3 Pt 1):786–789.
  • Keay S, Warren JW, Zhang CO, et al. Antiproliferative activity is present in bladder but not renal pelvic urine from interstitial cystitis patients. J Urol. 1999;162(4):1487–1489.
  • Conrads TP, Tocci GM, Hood BL, et al. CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients. J Biol Chem. 2006;281(49):37836–37843.
  • Kim J, Keay SK, Freeman MR. Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation. BJU Int. 2009;103(4):541–546.
  • Slobodov G, Feloney M, Gran C, et al. Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. J Urol. 2004;171(4):1554–1558.
  • Heinrich M, Oberbach A, Schlichting N, et al. Cytokine effects on gap junction communication and connexin expression in human bladder smooth muscle cells and suburothelial myofibroblasts. PLoS One. 2011;6(6):e20792.
  • Birder LA, Wolf-Johnston A, Buffington CA, et al. Altered inducible nitric oxide synthase expression and nitric oxide production in the bladder of cats with feline interstitial cystitis. J Urol. 2005;173(2):625–629.
  • Lavelle JP, Meyers SA, Ruiz WG, et al. Urothelial pathophysiological changes in feline interstitial cystitis: a human model. Am J Physiol Renal Physiol. 2000;278(4):F540–553.
  • Zeng Y, Wu XX, Homma Y, et al. Uroplakin III-delta4 messenger RNA as a promising marker to identify nonulcerative interstitial cystitis. J Urol. 2007;178(4 Pt 1):1322–1327; discussion 27.
  • Denk F, McMahon SB. Chronic pain: emerging evidence for the involvement of epigenetics. Neuron. 2012;73(3):435–444.

* This review contains the perspective of the pathophysiology of chronic pain, which can be applied to the pathogenesis of IC/BPS symptoms.

  • Kairys AE, Schmidt-Wilcke T, Puiu T, et al. Increased brain gray matter in the primary somatosensory cortex is associated with increased pain and mood disturbance in patients with interstitial cystitis/painful bladder syndrome. J Urol. 2015;193(1):131–137.
  • Yoshimura N, Oguchi T, Yokoyama H, et al. Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21(Suppl 1):18–25.
  • Foster HE Jr, Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183(5):1853–1858.
  • van Ophoven A, Pokupic S, Heinecke A, et al. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172(2):533–536.
  • Hertle L, van Ophoven A. Long-term results of amitriptyline treatment for interstitial cystitis. Aktuelle Urol. 2010;41(Suppl 1):S61–65.
  • Nickel JC, Barkin J, Forrest J, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology. 2005;65(4):654–658.
  • Davis EL, El Khoudary SR, Talbott EO, et al. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urol. 2008;179(1):177–185.
  • Neuhaus J, Schwalenberg T. Intravesical treatments of bladder pain syndrome/interstitial cystitis. Nat Rev Urol. 2012;9(12):707–720.

* This is a comprehensive summary of the current status of intravesical treatment of IC/BPS

  • Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140(1):36–39.
  • Peeker R, Haghsheno MA, Holmang S, et al. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000;164(6):1912–1915; discussion 15–6.
  • Sairanen J, Leppilahti M, Tammela TL, et al. Evaluation of health-related quality of life in patients with painful bladder syndrome/interstitial cystitis and the impact of four treatments on it. Scand J Urol Nephrol. 2009;43(3):212–219.
  • Hung MJ, Chen YT, Shen PS, et al. Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J. 2012;23(11):1533–1539.
  • Stav K, Beberashvili I, Lindner A, et al. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology. 2012;80(1):61–65.
  • Parsons CL, Housley T, Schmidt JD, et al. Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994;73(5):504–507.
  • Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med. 2012;9(1):207–212.
  • Nickel JC, Moldwin R, Lee S, et al. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103(7):910–918.
  • Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–875; discussion 75.
  • Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104(5):657–661.
  • Giannantoni A, Mearini E, Del Zingaro M, et al. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Curr Drug Deliv. 2010;7(1):1–4.
  • Pinto R, Lopes T, Costa D, et al. Ulcerative and nonulcerative forms of bladder pain syndrome/interstitial cystitis do not differ in symptom intensity or response to onabotulinum toxin A. Urology. 2014;83(5):1030–1034.
  • Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005;174(6):2235–2238.
  • Forsell T, Ruutu M, Isoniemi H, et al. Cyclosporine in severe interstitial cystitis. J Urol. 1996;155(5):1591–1593.
  • Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2004;171(6 Pt 1):2138–2141.
  • Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012;188(4):1186–1191.
  • Ottem DP, Teichman JM. What is the value of cystoscopy with hydrodistension for interstitial cystitis? Urology. 2005;66(3):494–499.
  • Erickson DR, Kunselman AR, Bentley CM, et al. Changes in urine markers and symptoms after bladder distention for interstitial cystitis. J Urol. 2007;177(2):556–560.
  • Oravisto KJ. Epidemiology of interstitial cystitis. Ann Chir Gynaecol Fenn. 1975;64(2):75–77.
  • Bade JJ, Rijcken B, Mensink HJ. Interstitial cystitis in The Netherlands: prevalence, diagnostic criteria and therapeutic preferences. J Urol. 1995;154(6):2035–2037; discussion 37–8.
  • Clemens JQ, Meenan RT, Rosetti MC, et al. Prevalence and incidence of interstitial cystitis in a managed care population. J Urol. 2005;173(1):98–102; discussion 02.
  • Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–544.
  • Anger JT, Zabihi N, Clemens JQ, et al. Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome. Int Urogynecol J. 2011;22(4):395–400.
  • Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001;57(6 Suppl 1):47–55.
  • Erickson DR, Tomaszewski JE, Kunselman AR, et al. Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndrome. J Urol. 2008;179(5):1850–1856.

** This article described the difference in inflammatory changes of the bladder between IC/BPS with Hunner’s lesion and that without

  • Tyagi P, Killinger K, Tyagi V, et al. Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol. 2012;187(6):2243–2248.
  • Sukiennik A, Carr DB, Bonney I, et al. The effect of short-term epidural local anesthetic blockade on urinary levels of substance P in interstitial cystitis. Anesth Analg. 2004;98(3):846–850, table of contents.
  • Lazzeri M, Beneforti P, Benaim G, et al. Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J Urol. 1996;156(3):947–952.
  • Lazzeri M, Beneforti P, Spinelli M, et al. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol. 2000;164(3 Pt 1):676–679.
  • Payne CK, Mosbaugh PG, Forrest JB, et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol. 2005;173(5):1590–1594.
  • Levi-Montalcini R, Skaper SD, Dal Toso R, et al. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996;19(11):514–520.
  • Freund-Michel V, Frossard N. The nerve growth factor and its receptors in airway inflammatory diseases. Pharmacol Ther. 2008;117(1):52–76.
  • Lowe EM, Anand P, Terenghi G, et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997;79(4):572–577.
  • Okragly AJ, Niles AL, Saban R, et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol. 1999;161(2):438–441; discussion 41–2.
  • Qu HC, Zhang W, Yan S, et al. Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis. PLoS One. 2014;9(9):e106321.
  • Dmitrieva N, Shelton D, Rice AS, et al. The role of nerve growth factor in a model of visceral inflammation. Neuroscience. 1997;78(2):449–459.
  • Chuang YC, Fraser MO, Yu Y, et al. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol. 2001;165(3):975–979.
  • Seki S, Sasaki K, Fraser MO, et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol. 2002;168(5):2269–2274.
  • Yoshimura N, de Groat WC. Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation. J Neurosci. 1999;19(11):4644–4653.
  • Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(5):1716–1721.
  • Kashyap M, Kawamorita N, Tyagi V, et al. Down-regulation of nerve growth factor expression in the bladder by antisense oligonucleotides as new treatment for overactive bladder. J Urol. 2013;190(2):757–764.
  • Erickson DR, Xie SX, Bhavanandan VP, et al. A comparison of multiple urine markers for interstitial cystitis. J Urol. 2002;167(6):2461–2469.
  • Peters KM, Diokno AC, Steinert BW. Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guerin treat interstitial cystitis by altering the immune profile in the bladder? Urology. 1999;54(3):450–453.
  • Keay S. Cell signaling in interstitial cystitis/painful bladder syndrome. Cell Signal. 2008;20(12):2174–2179.
  • Ueda T, Tamaki M, Ogawa O, et al. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T. J Urol. 2000;164(6):1917–1920.
  • te Velde AA, Huijbens RJ, Heije K, et al. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood. 1990;76(7):1392–1397.
  • Gautam S, Tebo JM, Hamilton TA. IL-4 suppresses cytokine gene expression induced by IFN-gamma and/or IL-2 in murine peritoneal macrophages. J Immunol. 1992;148(6):1725–1730.
  • Logadottir Y, Delbro D, Fall M, et al. Cytokine expression in patients with bladder pain syndrome/interstitial cystitis ESSIC type 3C. J Urol. 2014;192(5):1564–1568.
  • Rotondi M, Chiovato L, Romagnani S, et al. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28(5):492–520.
  • Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187(1):129–134.
  • Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998;187(6):875–883.
  • Sakthivel SK, Singh UP, Singh S, et al. CXCL10 blockade protects mice from cyclophosphamide-induced cystitis. J Immune Based Ther Vaccines. 2008;6(1):6.
  • Ogawa T, Homma T, Igawa Y, et al. CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol. 2010;183(3):1206–1212.
  • Corcoran AT, Yoshimura N, Tyagi V, et al. Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol. 2013;31(1):241–246.
  • Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014;191(1):77–82.
  • Funahashi Y, Oguchi T, Goins WF, et al. Herpes simplex virus vector mediated gene therapy of tumor necrosis factor-alpha blockade for bladder overactivity and nociception in rats. J Urol. 2013;189(1):366–373.
  • Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22(5):417–442.
  • Hansen HC. Interstitial cystitis and the potential role of gabapentin. South Med J. 2000;93(2):238–242.
  • Sasaki K, Smith CP, Chuang YC, et al. Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. Tech Urol. 2001;7(1):47–49.
  • Nickel JC, Crossland A, Davis E, et al. Investigation of a Ca2+ channel alpha2delta ligand for the treatment of interstitial cystitis: results of a randomized, double-blind, placebo controlled phase II trial. J Urol. 2012;188(3):817–823.
  • Nickel JC, Hanno P, Kumar K, et al. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology. 2012;79(6):1220–1224.
  • Gregoriadis G, Ryman BE. Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Biochem J. 1971;124(5):58P.
  • Gregoriadis G, Jain S, Papaioannou I, et al. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int J Pharm. 2005;300(1–2):125–130.
  • Chuang YC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009;182(4):1393–1400.
  • Cockayne DA, Hamilton SG, Zhu QM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000;407(6807):1011–1015.
  • Vlaskovska M, Kasakov L, Rong W, et al. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci. 2001;21(15):5670–5677.
  • Sun Y, Chai TC. Effects of dimethyl sulphoxide and heparin on stretch-activated ATP release by bladder urothelial cells from patients with interstitial cystitis. BJU Int. 2002;90(4):381–385.
  • Sun Y, Keay S, De Deyne PG, et al. Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J Urol. 2001;166(5):1951–1956.
  • Sun Y, Chai TC. Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. J Urol. 2004;171(1):448–452.
  • Sun Y, Chai TC. Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis. Am J Physiol Cell Physiol. 2006;290(1):C27–34.
  • Birder LA, Barrick SR, Roppolo JR, et al. Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. Am J Physiol Renal Physiol. 2003;285(3):F423–429.
  • Erickson DR, Propert KJ. Pregnancy and interstitial cystitis/painful bladder syndrome. Urol Clin North Am. 2007;34(1):61–69.
  • Black LV, Ness TJ, Robbins MT. Effects of oxytocin and prolactin on stress-induced bladder hypersensitivity in female rats. J Pain. 2009;10(10):1065–1072.
  • Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4(143):143ra00.
  • Stenton GR, Mackenzie LF, Tam P, et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol. 2013;168(6):1506–1518.
  • Rajasekaran M, Locke KW, Parsons CL. MN-001, a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model. BJU Int. 2006;98(2):430–434.
  • Yoshimura N, Miyazato M, Kitta T, et al. Central nervous targets for the treatment of bladder dysfunction. Neurourol Urodyn. 2014;33(1):59–66.
  • Glazer EJ, Basbaum AI. Leucine enkephalin: localization in and axoplasmic transport by sacral parasympathetic preganglionic neurons. Science. 1980;208(4451):1479–1481.
  • Dray A, Nunan L, Wire W. Central delta-opioid receptor interactions and the inhibition of reflex urinary bladder contractions in the rat. Br J Pharmacol. 1985;85(3):717–726.
  • Yokoyama H, Sasaki K, Franks ME, et al. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin. Hum Gene Ther. 2009;20(1):63–71.
  • Yokoyama H, Oguchi T, Goins WF, et al. Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception. Hum Gene Ther. 2013;24(2):170–180.
  • Godfrey L, Yan L, Clarke GD, et al. Modulation of paracetamol antinociception by caffeine and by selective adenosine A2 receptor antagonists in mice. Eur J Pharmacol. 2006;531(1–3):80–86.
  • Hussey MJ, Clarke GD, Ledent C, et al. Reduced response to the formalin test and lowered spinal NMDA glutamate receptor binding in adenosine A2A receptor knockout mice. Pain. 2007;129(3):287–294.
  • Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol. 2003;69(5):313–340.
  • Miyazato M, Sugaya K, Nishijima S, et al. Intrathecal or dietary glycine inhibits bladder and urethral activity in rats with spinal cord injury. J Urol. 2005;174(6):2397–2400.
  • Miyazato M, Sugaya K, Nishijima S, et al. Changes of bladder activity and glycine levels in the lumbosacral cord after partial bladder outlet obstruction in rats. Int J Urol. 2008;15(9):843–847.
  • Nishijima S, Sugaya K, Fukuda T, et al. Serum amino acids as indicators of cerebrospinal neuronal activity in patients with micturition disorders. Int J Urol. 2006;13(12):1479–1483.
  • Zafra F, Gomeza J, Olivares L, et al. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci. 1995;7(6):1342–1352.
  • Dohi T, Morita K, Kitayama T, et al. Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain. Pharmacol Ther. 2009;123(1):54–79.
  • Haranishi Y, Hara K, Terada T, et al. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. Anesth Analg. 2010;110(2):615–621.
  • Yoshikawa S, Oguchi T, Funahashi Y, et al. Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats. Eur Urol. 2012;62(4):704–712.
  • Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl. 2010;85:27–39.
  • Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6(7):521–532.
  • Schafers M, Svensson CI, Sommer C, et al. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci. 2003;23(7):2517–2521.
  • Sommer C, Lindenlaub T, Teuteberg P, et al. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res. 2001;913(1):86–89.
  • Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol. 1998;151(1):138–142.
  • Fink DJ, Wechuck J, Mata M, et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol. 2011;70(2):207–212.
  • Behr-Roussel D, Gorny D, Mevel K, et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol. 2005;47(1):87–91.
  • Bittencourt JA, Tano T, Gajar SA, et al. Relaxant effects of sildenafil on the human isolated bladder neck. Urology. 2009;73(2):427–430.
  • Roehrborn CG, Kaminetsky JC, Auerbach SM, et al. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int. 2010;105(4):502–507.
  • Kitta T, Tanaka H, Mitsui T, et al. Type 4 phosphodiesterase inhibitor suppresses experimental bladder inflammation. BJU Int. 2008;102(10):1472–1476.
  • Chen H, Wang F, Chen W, et al. Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of a randomized, double-blind, placebo-controlled trial–treatment of interstitial cystitis/painful bladder syndrome with low-dose sildenafil. Urology. 2014;84(1):51–56.
  • van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–67.
  • Ueda T, Nakagawa M, Okamura M, et al. New cystoscopic diagnosis for interstitial cystitis/painful bladder syndrome using narrow-band imaging system. Int J Urol. 2008;15(12):1039–1043.
  • Nickel JC, Irvine-Bird K, Jianbo L, et al. Phenotype-directed management of interstitial cystitis/bladder pain syndrome. Urology. 2014;84(1):175–179.
  • * This study shows the classification of IC/BPS symptoms that can be used to develop the tailored approach for IC/BPS treatment.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.